射频消融术和<sup>131</sup>I-肿瘤细胞核人鼠嵌合单抗治疗肺癌

张金山; 邓咏梅; 张金山; 邓咏梅

doi:10.3760/cma.j.issn.1673-4114.2009.03.008

[1]

邹小农.中国肺癌流行病学.中华肿瘤防治杂志,2007,14(12):881-883.

[2]

白春学,张新.肺癌的治疗现状.中华结核和呼吸杂志,2006,29(3):146-148.

[3]

Matsunka T, Okuma T. CT-guided radioffequency ablation for tung cancer. Int J Clin Oncol, 2007, 12(2):71-78.

[4]

Dupuy DE, Zagoria RJ, Akerley W, et al. Percutaneous radiofrequency ablation of malignancies in the lung. Am J Roentgenol, 2000, 174(1):57-59.

[5]

殷伟强,何建行,徐鑫,等.CT定位下经皮穿刺射频消融治疗肺肿瘤疗效分析.中国实用外科杂志,2006,26(3):219-221.

[6]

肖越勇,李家开,田锦林,等.CT导向下周围型肺癌射频消融治疗的临床分析.中华放射学杂志,2006,40(12):1317-1319.

[7]

Gadaleta C, Mattiuli V, Colueei G, et al. Radiofrequency ablation of 40 lung neoplasms:preliminary results. Am J Roentgenol, 2004, 183(2):361-368.

[8]

Laganà D, Carrafiello G, Mangini M, et al. Radiofrequency ablation of primary and metastatic lung tumors:preliminary experience with a single center device. Surg Endosc, 2006, 20(8):1262-1267.

[9]

Akeboshi M, Yainakado K, Nakatsuka A, et al. Percutaneous radinfrequency ablation of lung neoplasms:initial therapeutic response. J Vase lnterv Radiol, 2004, 15(5):463-470.

[10]

Yamakado K, Hase S, Matsuoka T, et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with eolorectal cancer:a multieenter study in Japan. J Vase lnterv Radiol, 2007, 18(3):393-398.

[11]

Ambrogi MC, Lucchi M, Dini P, et al. Percutaneous radiofrequency ablation of lung tumours:results in the mid-term. Eur J Cardiothorac Surg, 2006, 30(1):177-183.

[12]

Pennathur A, Luketich JD, Abbas G, et al. Radioffequeney ahlation for the treatment of stage I ram-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg, 2007, 134(4):857-864.

[13]

Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation tollowed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. Chest, 2006, 129(3):738-745.

[14]

de Babère T, Palussière J, Aupérin A, et al. Midterm local efficacy and survival after radiofrequeney ablation of lung tumors with minimum follow-up of 1 year:prospective evaluation. Radiology, 2006, 240(2):587-596.

[15]

Hiraki T, Tajiri N, Mimura H, et al. Pneumothorax, pleural effusion, and chest tube placement after radiofrequeney ablation of lung tumors:incidence and risk factors. Radiology, 2006, 241(1):275-283.

[16]

Nomura M, Yamakado K, Nomoto Y, et al. Complications after lung radiofrequency ablation:risk factors tor lung inflammation. Br J Radiol, 2008, 81(963):244-249.

[17]

Hataji O, Yamakado K, Nakatsuka A, et al. Radiological and pathological correlation of lung malignant tumors treated with percutaneous radiofrequency ablation. Intern Med, 2005, 44(8):865-869.

[18]

Steinke K, Haghighi KS, Wulf S, et al. Effect of vessel diameter on the creation of ovine lung radiofrequency lesions in vivo:preliminary results. J Surg Res, 2005, 124(1):85-91.

[19]

Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med, 2004, 34(1 suppl 1):4-9.

[20]

Dillman, RO. Radiolabeled anti-CD20 monolonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol, 2002, 20(16):3545-3557.

[21]

Kennel SJ, Davis IA, Branning J, et al. High resolution computed tomography and MR1 for monitoring lung tumor growth in mice undergoing radioimmunotherapy:correlation with histology. Med Phys, 2000, 27(5):1101-1107.

[22]

Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med, 2002, 43(5):693-713.

[23]

Goldenberg DM. Advaneing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother, 2003, 52(5):281-296.

[24]

von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Ann Rev Med, 2003, 54:343-369.

[25]

Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res, 1988, 48(20):5842-5848.

[26]

Khawli LA, Alauddin MM, Hu P, et al. Tumor targeting properties of indium-Ill labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. Cancer Biother Radiopharm, 2003, 18(6):931-940.

[27]

傅相平,李安民,张志文,等.¹³¹I-肿瘤细胞核人鼠嵌合单抗脑胶质瘤瘤内放免治疗研究.中华实验外科杂志,2005,22(1):102-103.

[28]

于力克,徐兆强,陈文萍,等.¹³¹I-chTNT导向治疗晚期肺癌的临床研究.中国肺癌杂志,2002,5(6):931-940.

[29]

Yu L, Ju DW, Chen W, et al. ¹³¹I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm, 2006, 21(1):5-14.

[30]

Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol, 2005, 23(7):1538-1547.